Impact of postoperative duration of Aspirin use on longevity of bioprosthetic pulmonary valve in patients who underwent congenital heart disease repair.
CONCLUSION: Our results indicated no benefit from long-term aspirin medication (>6 months) in patients who underwent PVR with a bioprosthetic valve.
PMID: 27895692 [PubMed - in process]
Source: Korean Journal of Pediatrics - Category: Pediatrics Tags: Korean J Pediatr Source Type: research
More News: Aspirin | Cardiology | Gastroschisis Repair | Heart | Heart Disease | Heart Valve Surgery | Pediatrics | Study